• Markets
    • icon
  • Companies
FRE · ASX

Firebrick Pharma Limited (ASX:FRE)

AU$0.061

 0.002 (3.39%)
ASX:Live
30/11/2023 04:10:33 PM
Hammer Bullish HALO Ords GROWTH AUS Engulfing Bearish Big Candle (Realtime) +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

FRE Overview

FRE Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

FRE Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.0

Trade Value (12mth)

N/A

1 week

-7.81%

1 month

59.46%

YTD

-71.9%

1 year

-77.31%

All time high

N/A

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

N/A

Short Sell (% of issue)

N/A

FRE Announcements

Latest Announcements

Date Announcements

31 October 23

Firebrick Receives $1.81m R&D Tax Incentive

×

Firebrick Receives $1.81m R&D Tax Incentive

31 October 22

September 2022 Quarterly Activity Report & Appendix 4C

×

September 2022 Quarterly Activity Report & Appendix 4C

31 October 22

Firebrick Update on Nasodine Phase 3 Trial

×

Firebrick Update on Nasodine Phase 3 Trial

31 May 23

Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment

×

Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment

29 November 23

Nasodine COVID-19 Patent Granted in South Africa

×

Nasodine COVID-19 Patent Granted in South Africa

29 May 23

Update on Nasodine AAT Appeal Timetable

×

Update on Nasodine AAT Appeal Timetable

29 June 23

Firebrick Update on AAT Schedule

×

Firebrick Update on AAT Schedule

29 July 22

June 2022 Quarterly Activity Report & Appendix 4C

×

June 2022 Quarterly Activity Report & Appendix 4C

29 August 23

Appendix 4E & Annual Report FY23

×

Appendix 4E & Annual Report FY23

29 August 23

Corporate Governance Statement

×

Corporate Governance Statement

29 August 23

Appendix 4G

×

Appendix 4G

28 September 22

Notice of AGM and Closing Date for Director Nominations

×

Notice of AGM and Closing Date for Director Nominations

28 March 23

Application for quotation of securities - FRE

×

Application for quotation of securities - FRE

28 March 23

Cleansing Notice

×

Cleansing Notice

28 August 23

Response to ASX Price and Volume Query

×

Response to ASX Price and Volume Query

27 October 23

September 2023 Quarterly Activity Report & Appendix 4C

×

September 2023 Quarterly Activity Report & Appendix 4C

27 July 23

June 2023 Quarterly Activity Report & Appendix 4C

×

June 2023 Quarterly Activity Report & Appendix 4C

26 July 22

Firebrick Presents at Euroz Hartleys Healthcare Conference

×

Firebrick Presents at Euroz Hartleys Healthcare Conference

26 April 22

Firebrick starts COVID-19 trial of Nasodine

×

Firebrick starts COVID-19 trial of Nasodine

26 April 22

March 2022 Quarterly Activity Report & Appendix 4C

×

March 2022 Quarterly Activity Report & Appendix 4C

25 October 22

Nasodine Patent Granted in Singapore

×

Nasodine Patent Granted in Singapore

25 May 22

Firebrick Appoints Dr Richard Treagus as Director

×

Firebrick Appoints Dr Richard Treagus as Director

25 May 22

Nasodine Patent Granted in Malaysia

×

Nasodine Patent Granted in Malaysia

25 May 22

Proposed issue of securities - FRE

×

Proposed issue of securities - FRE

24 November 22

Constitution

×

Constitution

24 November 22

Notification regarding unquoted securities - FRE

×

Notification regarding unquoted securities - FRE

24 November 22

Notification regarding unquoted securities - FRE

×

Notification regarding unquoted securities - FRE

24 November 22

Change of Director's Interest Notice - Richard Treagus

×

Change of Director's Interest Notice - Richard Treagus

FRE Fundamentals

Per Share Records

Historical data

Forecasted data

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) AU$ Lock Lock Lock Lock -0.01 -0.02 -0.04 Lock Lock Lock
EPS (Fully Diluted) AU$ Lock Lock Lock Lock -0.01 -0.02 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -61.8 -56.2 -77.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS AU$ Lock Lock Lock Lock -0.01 -0.02 -0.04 Lock Lock Lock
FCFPS AU$ Lock Lock Lock Lock -0.01 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -59.4 -83.1 -86.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A -9.5 -21.9 Lock Lock Lock
DPS AU$ Lock Lock Lock Lock N/A 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock N/A 0 0 Lock Lock Lock
BPS AU$ Lock Lock Lock Lock 0.01 0.05 0.01 Lock Lock Lock
BPS (Tangible) AU$ Lock Lock Lock Lock 0.01 0.05 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 295.8 435.5 -71.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 169 169 170 Lock Lock Lock
Basic m Lock Lock Lock Lock 169 169 170 Lock Lock Lock

Financial Records

Historical data

Forecasted data

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A -79.9 Lock Lock Lock
Selling & General Expenses AU$m Lock Lock Lock Lock 3 5 7 Lock Lock Lock
Gross Income AU$m Lock Lock Lock Lock 0 N/A 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -72.8 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA AU$m Lock Lock Lock Lock -3 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -42.5 -65.4 -44.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -114,773.5 -825,809.6 Lock Lock Lock
Depreciation & Amortisation AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT AU$m Lock Lock Lock Lock -3 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -42.5 -65.6 -44.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -114,941.8 -826,956.6 Lock Lock Lock
Pretax Income AU$m Lock Lock Lock Lock -3 -5 -7 Lock Lock Lock
Income Taxes AU$m Lock Lock Lock Lock 0 -1 0 Lock Lock Lock
Net Income AU$m Lock Lock Lock Lock -2 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.8 -55.6 -79.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -92,054.1 -819,526.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow AU$m Lock Lock Lock Lock -2 -4 -6 Lock Lock Lock
Capital Expenditures AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow AU$m Lock Lock Lock Lock 3 10 1 Lock Lock Lock
Free Cash Flow AU$m Lock Lock Lock Lock -2 -4 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -98.2 -116.9 -36.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -1,026.9 -6,969.8 Lock Lock Lock
Franking Balance AU$m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments AU$m Lock Lock Lock Lock 1 7 2 Lock Lock Lock
Total Assets AU$m Lock Lock Lock Lock 2 9 3 Lock Lock Lock
Long Term Debt AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt AU$m Lock Lock Lock Lock -1 -7 -2 Lock Lock Lock
Total Liabilities AU$m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Equity AU$m Lock Lock Lock Lock 2 8 2 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 2 8 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 295.8 435.5 -70.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -138.5 -43.5 -228.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -157.8 -45.9 -274.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -295.5 -96.5 -127.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -251.9 -77.3 -126.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -199.9 -85.5 -107.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A -1,142.2 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.4 1.5 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -74.5 -86.3 -95.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 7.8 18.5 5.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 7.8 18.5 5.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 69.0 85.8 90.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -901.4 -933.6 -1,142.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A 879.5 23,793.3 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A -118,223.5 -822,143.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A -55.9 -228.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -138.5 -43.5 -228.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -157.8 -45.9 -274.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock N/A 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock N/A -45.9 -274.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A 70,130.6 268,034.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A 70,130.6 268,034.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 82,954.5 N/A 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -82,954.5 70,130.6 268,034.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

FRE Shortsell

Frequently Asked Questions

The current share price of Firebrick Pharma Limited (FRE:ASX) is AU$0.061.
The 52-week high share price for Firebrick Pharma Limited (FRE:ASX) is AU$0.00.
The 52-week low share price for Firebrick Pharma Limited (FRE:ASX)? is AU$0.00.
Firebrick Pharma Limited (FRE:ASX) does not pay a dividend.
Firebrick Pharma Limited (FRE:ASX) does not pay a dividend.
Firebrick Pharma Limited (FRE:ASX) does not offer franking credits.
Firebrick Pharma Limited (FRE:ASX) is classified in the Healthcare.
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.